| abstract |
The present invention is concerned with novel indol-3-yl-carbonyl-azaspiropiperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention is concerned with compounds of the general formula (I) n n n n n n n n n n wherein R 1 to R 6 , U, V, W, X, Y and Z are as defined in the specification. |